|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.||Chairman of Management Board & CEO||1,32M||N/D||1968|
|Dr. Cord Dohrmann Ph.D.||Chief Scientific Officer & Member of Management Board||804k||N/D||1964|
|Dr. Craig Johnstone Ph.D.||COO & Member of Management Board||712k||N/D||1970|
|Dr. Matthias Evers Ph.D.||Chief Bus. Officer & Member of Management Board||636k||N/D||1973|
|Ms. Laetitia Rouxel||CFO & Member of Management Board||N/D||N/D||1974|
|Ms. Anja Bosler||Principal Accounting Officer and Sr. VP of Group Accounting||N/D||N/D||N/D|
|Mr. Volker Braun||Sr. VP and Global Head of Investor Relations & ESG||N/D||N/D||N/D|
|Dr. Christian Dargel||EVP Global Head of Legal & Compliance||N/D||N/D||N/D|
|Gabriele Hansen||Sr. VP & Head of Global Corp. Communications & Marketing||N/D||N/D||N/D|
|Ms. Monika Conradt||Global Head of HR||N/D||N/D||N/D|
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
L'ISS Governance QualityScore di Evotec SE al 1 settembre 2023 è 5. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 8.